KalVista Pharmaceuticals (KALV)

[Jk384]

7 Reasons Why you want to own CBYL now…

We have $1.63 in NET cash per share after debt on hand as of 3/31. 48 million cash 5 million debt equals 43 million in net cash on hand after debt with 26 million shares outstanding.

We own patents for Hydros-TA worldwide which isn't just for knee pain but check out other future uses in pipeline section on our website.

Phase 3 was not a complete failure just missed 2nd endpoint because pain level at 26 weeks was equal to another method still better at beginning of trial.

Therefore, patents hold value, add that to the $1.63 in NET cash per share for acquisition or merger.

They are actively seeking acquisition or merger per PR on 4/15/16 and only have 3 employees to preserve cash stockpile. Goal is to close by the end of Q3, which means PR should be any day now.

ZERO preferred shares outstanding per 10q which means when they get paid we get paid, only common shareholders.

Our new institutional investor Vivo Capital LLC, newly reported as of 3/31/16 specializes in facilitating strategic alliances including creating cross border partnerships & facilitating acquisitions. They own over 4.2 million shares, over 15% of all outstanding shares.

Links

10q

http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11382259&RcvdDate=5/12/2016&CoName=CARBYLAN%20THERAPEUTICS%2C%20INC.&FormType=10-Q&View=html

PR regarding seeking acquisition or merger

http://www.nasdaq.com/press-release/carbylan-therapeutics-announces-decision-to-pursue-strategic-transaction-20160415-00182

Link in regards to Vivo Capital LLC

http://www.fiercemedicaldevices.com/story/vivo-capital-doubles-down-close-750m-us-china-healthcare-fund/2015-03-18

Link to Product Pipeline

http://www.carbylan.com/innovation/product-pipeline